Perrigo Stock Hits New 52-Week High (PRGO)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Perrigo Company (Nasdaq: PRGO) hit a new 52-week high Wednesday as it is currently trading at $121.18, above its previous 52-week high of $121.12 with 467,823 shares traded as of 3:26 p.m. ET. Average volume has been 513,000 shares over the past 30 days.

Perrigo has a market cap of $11.23 billion and is part of the health care sector and drugs industry. Shares are up 14.8% year to date as of the close of trading on Tuesday.

Perrigo Company, through its subsidiaries, develops, manufactures, and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, and active pharmaceutical ingredients (API) worldwide. The company has a P/E ratio of 26.2, above the S&P 500 P/E ratio of 17.7.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates Perrigo as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full Perrigo Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE.
null

If you liked this article you might like

McDonald's Takes Bite Out of Dow, but Nasdaq and S&P 500 at Records

Perrigo Stock Jumps as Starboard's Smith Says Generic Drugs a Strong Business

Valeant CEO Confident Divestitures Can Successfully Pare Debt, Skeptics Remain

These Stocks Have Changed Direction

Stocks Tank as Trump, North Korea Exchange Barbs